comparemela.com

Latest Breaking News On - Biohaven pharmaceutical holding company - Page 10 : comparemela.com

Shareholder Alert - The M&A Class Action Firm Announces an Investigation of BioHaven Pharmaceutical Holding Company Ltd

Weekly Life Science News Round Up: 9th – 13th May

Pfizer to shell out $11 6B for migraine drugmaker Biohaven

Pfizer announced that it has entered into an agreement to acquire Biohaven, which is best known for Nurtec ODT migraine therapy.

Ground News - Pfizer to buy migraine drugmaker Biohaven in $11 6 billion deal

Pfizer Inc said on Tuesday it will buy migraine drug maker Biohaven Pharmaceutical Holding Company Ltd for about $11.6 billion in cash, as the drugmaker seeks to beef up its portfolio ahead of patent losses for some cancer drugs. Through the deal, Pfizer will gain access to Biohaven's approved drug Rimegepant that belong to a class of migraine drugs known as calcitonin gene-related

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.